Friday Blog Roundup

Thereâs been a lot of blogging about vaccines lately:

Elsewhere:

Emily Monosson at The Neighborhood Toxicologist investigates EPAâs decisions about nanotechnology regulation.

David Roberts at Gristmill looks at the big stories emerging from the League of Conservation Votersâ just-released scorecard.

Roy M. Poses MD at Health Care Renewal delves into the torturous supply chain and inadequate oversight of Baxterâs heparin.

Maggie Mahar at Health Beat wonders where the doctors were during the âCholesterol Conâ thatâs now coming to light.

Merrill Goozner at GoozNews suggests a different approach that FDA could use regarding the approval of Avastin for breast cancer.

Lisa Codipoti at Womenstake uses a personal example to illustrate one of the problems with primary care in our current system.

Michael Kremer at Global Health Policy explains why mass treatment through schools is an effective use of the funds President Bush has pledged to invest in fighting neglected tropical diseases.

More like this

Nanotechnology is getting some attention these days. Revere at Effect Measure (which just celebrated its third blogiversary!) gauges the level of alarm about nanotechnology; at Science Progress, Michael Peroski looks at the current regulatory framework for nanotechnology, while Justin Masterman…
Bloggers are bringing us lots of drug news this week: Abel Pharmboy at Terra Sigillata explains why a decision by the Centers for Medicare and Medicaid Services is devastating news for lymphoma patients â and possibly for all cancer patients (here, too). Ed Silverman at Pharmalot considers the…
Thereâs a lot going on right now with the FDA and drug regulation: The Health Affairs Blog has posts by Scott Gottlieb (a former FDA official now at the American Enterprise Institute) and Jerome Kassirer (a former editor-in-chief of the New England Journal now at the Tufts University School of…
What's new at the FDA? Ed Silverman at Pharmalot reports on FDA plans to spend some of its user-fee money on post-marketing safety activities. Merrill Goozner at GoozNews warns that the FDA is scrapping the Helsinki Declaration on protecting human subjects. Jacob Goldstein at WSJ's Health Blog…

Great post, and I think the Chinese will do nothing that sounds remotely threatening to the Western companies producing drugs/food in China. And the FDA will continue to merely issue warnings and do nothing. Hard to be optimistic when your president is so partial to industry and indifferent to consumers.